

## IN THE CLAIMS

1. (previously presented) An isolated polypeptide of the severe acute respiratory syndrome (SARS) virus, wherein the polypeptide comprises a SARS virus Spike (S) polypeptide or a fragment thereof.
2. (currently amended) The polypeptide of claim 1, wherein the fragment comprises the S1 domain (~~SEQ ID NO: 7307~~ (SEQ ID NO: 7307), S2 domain (SEQ ID NO: 7308), the receptor binding region of the S1 domain, the oligomerization domain regions of the S2 domain, the leucine zipper region of the S2 domain, the membrane anchor region of the S1 domain, the hydrophobic domain region of the S2 domain, the cytoplasmic tail region of the S2 domain and/or any of the polypeptide sequences given in SEQ ID NOs: 7193-7194, 7196-7199, 7207-7223, 7398, 7399 and 8041-8240.
3. (previously presented) The polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence selected from SEQ ID NO<sup>s</sup>: 6042, or 9962.
4. (previously presented) The polypeptide of claim 1, wherein the polypeptide is in oligomeric form.
5. (previously presented) The polypeptide of claim 4, wherein the oligomer is a trimer.
6. (previously presented) The polypeptide of claim 1, wherein the polypeptide is a fusion peptide.
7. (previously presented) The polypeptide of claim 6, wherein the fusion peptide comprises the Spike protein (SEQ ID NO: 6042) or fragment thereof.
8. (previously presented) The polypeptide of claim 7, wherein the fusion peptide

comprises a tag sequence, a second SARS virus protein, a non-SARS virus protein, a bacterial protein and/or an adjuvant.

9-21. (canceled)

22. (previously presented) A vaccine for the treatment or prevention of severe acute respiratory syndrome (SARS), comprising an isolated or purified polypeptide comprising the SARS virus Spike protein or a fragment thereof.

23. (previously presented) The vaccine of claim 22, comprising an isolated polypeptide according to any one of claims 2 to 8 and 121 to 126.

24. (canceled)

25. (previously presented) The vaccine of claim 22, further comprising an adjuvant.

26. (original) The vaccine of claim 25, wherein the adjuvant is an aluminium salt or is MF59.

27. (previously presented) The vaccine of claim 22, comprising more than one SARS virus antigen.

28. (original) The vaccine of claim 27, wherein the antigens are selected from S, E, N and M.

29-93. (canceled)

94. (currently amended) [[A]] An isolated polypeptide comprising an immunogenic, surface exposed fragment of the amino acid sequence SEQ ID NO: 6042.

95. (original) The polypeptide of claim 94, wherein said fragment does not include the last 50 amino acids of the C-terminus of SEQ ID NO: 6042.

96. (currently amended) The polypeptide of claim 94, wherein said fragment does not include a ~~transdomain~~ transmembrane domain region of SEQ ID NO: 6042.

97. (original) The polypeptide of claim 94, wherein said fragment does not include a C-terminus cytoplasmic domain of SEQ ID NO: 6042.
98. (original) The polypeptide of claim 94, wherein said fragment does not include a N-terminus signal sequence.
- 99-113. (canceled)
114. (currently amended) [[A]] The vaccine of claim [[22]] 23 further comprising an adjuvant.
115. (previously presented) The vaccine of claim 114 wherein the adjuvant is a detoxified bacterial ADP-ribosylating toxin, a non-toxic double mutant form of *Bordella pertussis* toxoids, chitosan, MF59, aluminium, and aluminium salt or a SMIP.
116. (canceled)
117. (previously presented) A method of vaccinating a subject comprising administering to the subject a vaccine of claim 22.
- 118-120. (canceled)
121. (withdrawn) The polypeptide of claim 8, wherein the second SARS virus protein comprises ORF1a (SEQ ID NO: 6039), ORF1b (SEQ ID NOs: 7188 and 7189), ORF1ab polyprotein (SEQ ID NO: 6041), Matrix protein (SEQ ID NO: 6046), Nucleocapsid protein (SEQ ID NOs: 6051 and 6052), 3CLp protease (SEQ ID NOs: 6569 and 9769), small membrane protein (SEQ ID NO: 6045), any of the hypothetical proteins given in SEQ ID NOs: 6050, 6049, 6048, 6047, 6044, 6043 and 6040, or a fragment thereof.
122. (withdrawn) The polypeptide of claim 121, wherein the fragment of the second

SARS virus protein comprises any of the polypeptides given in SEQ ID NOs: 2206-2224, 3020-3042, 7180-7817, 7257-7264, 9764-9765, or any of the T-cell epitopes given in SEQ ID NOs: 7400-8040, 8281-9752.

123. (withdrawn) The polypeptide of claim 8, wherein the non-SARS virus protein is derived from a coronavirus, influenza virus, rhinovirus, parainfluenza virus, respiratory syncytial virus, adenovirus and/or metapneumovirus.
124. (withdrawn) The polypeptide of claim 8, wherein the bacterial protein is a bacterial adhesion protein or fragment thereof.
125. (withdrawn) The polypeptide of claim 124, wherein the bacterial adhesion protein is NadA, YadA, USpA2 or a NadA-like protein.
126. (withdrawn) The polypeptide of claim 124, wherein the fusion protein comprises an amino acid sequence given in any of SEQ ID NOs: 7197-7206 or SEQ ID NOs: 7302-7306.
127. (new) A vaccine for the treatment or prevention of severe acute respiratory syndrome (SARS) comprising an isolated polypeptide, wherein the polypeptide comprises a fragment of SEQ ID NO:6042, wherein said fragment does not include up to 70 amino acids of the C-terminus.
128. (new) The vaccine of claim 127 further comprising the adjuvant MF59.
129. (new) The polypeptide of claim 94, wherein said fragment does not include a transmembrane domain region and a C-terminal cytoplasmic domain of SEQ ID NO: 6042.
130. (new) The polypeptide of claim 94 wherein the fragment does not include up to 70 amino acids of the C-terminus.

131. (new) The polypeptide of claim 1, wherein said fragment does not include a transmembrane domain region and a C-terminal cytoplasmic domain.
132. (new) The polypeptide of claim 1 wherein the fragment does not include up to 70 amino acids of the C-terminus.